Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew A Davis
Yale University Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- City of Hope at Irvine Lennar
Irvine, California, United States
- Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
- City of Hope Antelope Valley
Lancaster, California, United States
- Uc Irvine Health/chao Family Comprehensive Cancer Center
Orange, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- City of Hope South Pasadena
South Pasadena, California, United States
- City of Hope Upland
Upland, California, United States
- Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Ut Md Anderson Cancer Center
Houston, Texas, United States
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Oct 2022
- Primary completion
- 17 Sept 2025
- Completion
- 23 Jan 2027
- Last update posted
- 17 Jun 2026
- Registered enrollment
- 33
- Registry id
- NCT05372614
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.